.png)
Agenzia Italiana del Farmaco
Lojuxta (lomitapide): Reminder to monitor the liver function of patients treated with Lojuxta and to avoid use in pregnancy - Lojuxta (lomitapide): Reminder to monitor the liver function of patients treated with Lojuxta and to avoid use in pregnancy
Lojuxta (lomitapide): Reminder to monitor the liver function of patients treated with Lojuxta and to avoid use in pregnancy
Summary:
Healthcare professionals are reminded of the following in order to minimize the risks of Lojuxta (lomitapide):
- Lomitapide is contraindicated in patients with moderate or severe hepatic impairment and those with unexplained persistent abnormal liver function tests.
- Liver function should be monitored before and during treatment with lomitapide (see table below for specific recommendations).
- Screening for steatohepatitis/fibrosis should be performed before starting treatment with lomitapide and on an annual basis thereafter (see section below).
- Lomitapide is contraindicated during pregnancy.
- Before starting treatment with lomitapide in women of child-bearing potential:
- the absence of pregnancy should be confirmed,
- advice on effective methods of contraception should be provided,
- start and maintain effective contraception.
Published on: 17 February 2021
📊 Online “OsMed interattivo”, la piattaforma aggiornata con i dati più recenti su consumi e spesa d...
Vai al post →
Ogni anno il Rapporto OsMed offre una fotografia aggiornata dell’uso dei #farmaci in Italia.
Un ins...
Vai al post →
“Se non sei un medico, non fare il medico.”
Uno slogan semplice, ma che nasce da un problema ancora ...
Vai al post →
🗞️ Oggi a Milano una giornata significativa per l’Agenzia Italiana del Farmaco: per la prima volta ...
Vai al post →
AIFA e Procura di Velletri firmano il protocollo d’intesa per il contrasto alla violenza di genere
...
Vai al post →
💊 Se non sei un medico, non fare il medico. L’uso improprio degli #antibiotici ne limita l’efficaci...
Vai al post →
